pirenzepine has been researched along with Chemical Dependence in 9 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders." | 9.09 | Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001) |
| "The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders." | 5.09 | Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| " The patient was previously treated with olanzapine and developed priapism, which required emergency medical treatment." | 3.72 | Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. ( Weisman, RL, 2003) |
| "Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity." | 2.42 | Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. ( Potvin, S; Roy, JY; Stip, E, 2003) |
| "This study determines the extent of substance abuse in a treatment-resistant population and assesses the response of this population to olanzapine treatment." | 1.30 | Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. ( Conley, RR; Gale, EA; Kelly, DL, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mechanic, JA | 1 |
| Maynard, BT | 1 |
| Holloway, FA | 1 |
| Potvin, S | 1 |
| Stip, E | 1 |
| Roy, JY | 1 |
| Weisman, RL | 1 |
| Sattar, SP | 1 |
| Grant, K | 1 |
| Bhatia, S | 1 |
| Petty, F | 1 |
| Glazer, WM | 1 |
| Conley, RR | 1 |
| Kelly, DL | 1 |
| Gale, EA | 1 |
| Lindenmayer, JP | 1 |
| Patel, R | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Littrell, KH | 1 |
| Petty, RG | 1 |
| Hilligoss, NM | 1 |
| Peabody, CD | 1 |
| Johnson, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients[NCT00780702] | Phase 1 | 41 participants (Actual) | Interventional | 2008-05-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
2 reviews available for pirenzepine and Chemical Dependence
| Article | Year |
|---|---|
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.
Topics: Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition; Comorbi | 2003 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
2 trials available for pirenzepine and Chemical Dependence
| Article | Year |
|---|---|
Potential use of olanzapine in treatment of substance dependence disorders.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cocaine-Related Disorders; Huma | 2003 |
Olanzapine treatment for patients with schizophrenia and substance abuse.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine | 2001 |
5 other studies available for pirenzepine and Chemical Dependence
| Article | Year |
|---|---|
Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat.
Topics: Amphetamine; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Central Nervous Sys | 2003 |
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Black or African American; Contraindications; Diagnosi | 2003 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine-induced ketoacidosis with diabetes mellitus.
Topics: Antipsychotic Agents; Antisocial Personality Disorder; Benzodiazepines; Diabetes Mellitus; Diabetic | 1999 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |